ec.	7. 2017	1:14PM No. 5261 Created with a trial version of Syncfusion Essential PDF	Ρ.
-----	---------	--	----




Risk ManagomonVnem/August 2012

No. 2280

7

Informed Consent for Infusion Center Treatment



Page 1 of 1

Jan. 20. 2016 9:42AM

	•,					,
eroby give my consont and author societes or assistants and Orange I	rize: Dr Roglonal Mor	Ka ma Ilahi Conte	dus my	and those w	the he/she may do	osignate as
aument upon: HoSDA6	THI AN.	ijĖĞ	**		<u> </u>	<u>.</u>
C.	Patient's name					,
escribe the treatment in both clini	ical and layer	en's terms.	No Астопуйц «	or Abbreviations): ——	. •	
Asked 402	nep	گىدى	us home	eply		
day	diano	 	·		•	
ive permission with full knowled	se and under	standing the	creof. I underste	nd that medicine i	s not an exact sol	ance and that
re is the possibility that the treatment	ment may not	have the b	enefils or results	intended. I am air	90 Awaro that the	re are always
ks and dangers to life and health a usequences not ordinarily anticipa	eteq in eqaan easoomen ke	eq' prij 80.	r are, use or mec ve this permissic	ncanon, and treatn in with full assent :	wats which can d nevertheless.	Aust Boyerse
		,, -	- - -			
signing below, I confirm that I i	fully understa	nd the info	rmation provide	d to me, my questi	ons bave been an	swered, and l
ye my consent to the treatment(s)) eliócitico asi			•		
nicn/Health Care Agent/Surrogate/Over	Hen Blandfilm)		ated Neurc)	(Relationship	en Welfa-en (75-e	AM PM
HIGH HER HIS CATE VEGIN STILLS REGARDS		\s. \\.	,	(1/0/2001SIM)	to Patient) (Date	6) (Timo)
		7.			1 1	/ М / М
Witness Signature)		(P)	duted Name)		(Date	
		· , · ,				·
						, -
Mark this box if telephone	consent	i i	Mark this bo	ox if interpreter was	involved,	
Mark this box if telephone	consent		Mark this bo	x if interpreter wa	s involved,	· "
have discussed the nature and p	urpose and th	e regsonabl	iy foreseeable ric	ske and benefits of	the treatment(s),	the alternatives,
Mark this box if telephone have discussed the nature and proceeding not performing the treation the patient's legal representative	upoge and the	e redsonabl	iy foreseeable ric isks and benefit:	ske and benefits of	the treatment(s),	the alternatives, ed that the patient
have discussed the nature and procleding not performing the tree	upoge and the	e redsonabl	iy foreseeable ric isks and benefit:	ske and benefits of	the treatment(s),	the alternatives, ed that the patient
have discussed the nature and principled in the free the patient's legal representative.	urpose and the imenu(a), as we who algued	e reasonable vell as the r	ly foresceable ric isks and benefit: icratands them.	ske and benefits of s of the alternatives	the treatment(s),	the alternatives, ed that the patient
have discussed the nature and principled in the free the patient's legal representative.	urpose and the imenu(a), as we who algued	e reasonable vell as the r	ly foresceable ric isks and benefit: icratands them.	ske and benefits of s of the alternatives	the treatment(s),	the alternatives, led that the patient
have discussed the nature and principled in the free the patient's legal representative.	urpose and the imenu(a), as we who algued	e reasonable vell as the r	ly foresceable ric isks and benefit: icratands them.	ske and benefits of s of the alternatives	the treatment(s),	the alternatives, led that the patient
have discussed the nature and procleding not performing the tree	urpose and the imenu(a), as we who algued	e reasonable vell as the r	ly foresceable ric isks and benefit: icratands them.	ske and benefits of s of the alternatives	the treatment(s),	the alternatives, led that the patient / 1245

ORANGE REGIONAL MEDICA Physician Order For	AL CENTER m	HOS'DA B	HIAN,	YEG HICKE				
TT- //	QD μg QOD		11/17/19 has take	40				
OUTPATIENT DARBEPOETIN (Aranesp®) Eryth	ropoetic Stimulat	ing Agent (ES	A) Order Form				
Initial Hemoglobin (Hgb)/Hematocrit Current Hgb: Hct:	(Hct) Date/level:	·····		kg				
DIAGNOSIS (Check one):	····	···		······································				
☐ Chemotherapy induced anemia Hemoglobin (Hgb) / Hematocrit (Darbepoetin initial dose ≤ 2.25 n On week 4 doses may be increa By week 8 discontinue treatment	(Hct) must be < 10 g/ ncg/kg/week sed by 25% if Hab/Ha	ot rise is < 1/3.						
☐ End Stage Renal Disease (ESR	•		Hold A	a near to				
Chronic Kidney Disease (CRD) For chronic kldney disease creat Monitor to ensure transferring sa	inine ≥ 3 and CrCl <	80 mL/min r serum ferritin > 100	ng/mL	b > 1(grup				
□ HIV/AIDS anemia induced by z	idovudine or othe	r nucleoside rever	se transcriptas	e inhibitors				
Anemia related to myelodyspiastic syndrome (MDS) excluding AML and CML Bone marrow biopsy < 5% blasts Erythropoletin level 100 or less After 2 months of treatment consider discontinuing if there is no significant increase in Hgb/Hct and/or decreased transfusions								
☐ Treatment of anemia of selected chronic diseases Rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel diseases, and hepatitis C undergoing treatment								
initial Hgb/Hct must be < 10 g/dl a titrate dose of darbepoetin to main timed dose adjustment.	tain a target Hgb	of 10-12 g/dl and l	Hct of 30-36%	by appropriate				
Date of last ESA agent:	Do not give	Darbepoetin more	frequently the	n once weekly				
Drug	Dose (mcg)	Route	Frequency	RN/Time				
Darbepoetin (Aranesp [®])	40mcg	⊠SubQ □ IV	once a week					
Print Last Name RAMASWAMY Print Last Name: Physician Signature Nurse Signature: Date: Date 12-710 Time: Faxed Time Fexed								